OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Allen on Treatment Options in Advanced-Stage Hodgkin Lymphoma

January 13th 2020

Pamela Blair Allen, MD, MSc, discusses treatment options in advanced-stage Hodgkin lymphoma.

Dr. Shah on the Utility of MRD in Frontline Multiple Myeloma

January 13th 2020

Nina Shah, MD, discusses the utility of minimal residual disease in frontline multiple myeloma.

Dr. Schlumbrecht on the Role of Surgical Resection in Uterine Leiomyosarcoma

January 13th 2020

Matthew P. Schlumbrecht, MD, discusses the role of surgical resection in uterine leiomyosarcoma.

Dr. Coleman on Next Treatment Steps for Patients With Ovarian Cancer

January 13th 2020

Robert L. Coleman, MD, discusses the next steps of treatment for patients with high-grade serous ovarian cancer.

Dr. Janjigian on Data With Atezolizumab/Bevacizumab Combo in HCC

January 11th 2020

Yelena Y. Janjigian, MD, discusses the improvement in efficacy and toxicity with patients with hepatocellular carcinoma who are treated with bevacizumab and atezolizumab when compared with sorafenib.

Dr. Sznol on Immune-Related Toxicities in Melanoma

January 11th 2020

Mario Sznol, MD, discusses the adverse events that can occur from nivolumab in combination with ipilimumab for patients with melanoma.

Dr. Arellano on Managing Older Patients With AML

January 11th 2020

Martha L. Arellano, MD, discusses the management of older patients with acute myeloid leukemia.

Dr. Berger on Frontline Treatment Options in Newly Diagnosed Advanced Ovarian Cancer

January 11th 2020

Jessica Layne Berger, MD, discusses the frontline treatment options in newly diagnosed ovarian cancer.

Dr. Bochner on Standardizing Molecular Profiling in Bladder Cancer

January 11th 2020

Bernard H. Bochner, MD, FACS, discusses the potential standardization of molecular profiling in bladder cancer.

Dr. Burris on the Incorporation of Biosimilars in Oncology

January 10th 2020

Howard "Skip" A. Burris, III, MD, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the incorporation of biosimilars in oncology.

Dr. Dunavin on Treatment Considerations in Myelofibrosis

January 10th 2020

Neil Dunavin, MD, MS, assistant professor of medicine, School of Medicine, University of California, San Francisco (UCSF), UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment considerations in myelofibrosis.

Dr. Hamilton on the HER2CLIMB Trial in Metastatic HER2+ Breast Cancer

January 10th 2020

Erika P. Hamilton, MD, director, Breast Cancer and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the phase II HER2CLIMB trial in metastatic HER2-positive breast cancer.

Long-Term Follow-Up of Acalabrutinib in Patients With MCL and CLL

January 10th 2020

Kellie Ryan, MPH, discusses the importance of long-term follow-up with acalabrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

Dr. Lonial on the ICARIA-MM Trial in Heavily Pretreated Multiple Myeloma

January 10th 2020

Sagar Lonial, MD, FACP, discusses the ICARIA-MM trial in patients with multiple myeloma who experience early relapse, have been heavily pretreated, or have refractory disease.

Dr. Andreadis on CAR T-Cell Therapy in Relapsed/Refractory MCL

January 10th 2020

Charalambos (Babis) Andreadis, MD, MSCE, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Dr. Backes on Financial Toxicity Considerations in Ovarian Cancer

January 10th 2020

Floor J. Backes, MD, discusses the consideration of financial toxicity when choosing a PARP inhibitor for a patient with ovarian cancer.

Dr. Flaig on Immune Checkpoint Inhibitors in Advanced Bladder Cancer

January 10th 2020

Thomas W. Flaig, MD, discusses the utility of immune checkpoint inhibitors in advanced bladder cancer.

Dr. Fakhri on Selecting the Optimal Treatment in CLL

January 10th 2020

Bita Fakhri, MD, MPH, discusses considerations in selecting the optimal treatment in chronic lymphocytic leukemia.

Dr. Brammer on the Importance of MRD in Relapsed/Refractory ALL

January 10th 2020

Jonathan E. Brammer, MD, discusses the importance of achieving minimal residual disease negativity in relapsed/refractory acute lymphoblastic leukemia.

Dr. He on Future Treatment for Patients With Hepatocellular Carcinoma

January 10th 2020

Aiwu Ruth He, MD, discusses the combination regimen of bevacizumab and atezolizumab in patients with advanced-stage hepatocellular carcinoma.